Hiding in Plain Sight – Identify APOL1-Mediated Kidney Disease^†

Identify APOL1 variants associated with APOL1-mediated kidney disease (AMKD) with Renasight™ sponsored renal genetic testing for eligible* patients of African ancestry^††

Black Americans are 4 times more likely to develop kidney failure compared to other populations, raising the possibility of an underlying genetic contribution to this disparity^1,2

Genetic testing is a critical first step—genetic testing is the only way to confirm if a patient has AMKD.

Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible* patients of African ancestry diagnosed with chronic kidney disease^††

Get Started

Program Overview

Natera and Vertex Pharmaceuticals are working together to raise awareness about the genetic causes of kidney disease in the Black community and to reduce the barriers associated with genetic testing. Vertex Pharmaceuticals is sponsoring a no-cost testing program with Natera to provide the Renasight™ genetic test and genetic counseling to eligible* individuals. Through this program more patients will have access to genetic testing which may help to provide answers explaining the increased risk of kidney disease and provide clarity for improved disease management decisions.

Get Started

*Sponsored Renasight™ Genetic Testing Program Eligibility

Patients who meet all of the following criteria are eligible for the Renasight™ sponsored testing program:

Patients of African ancestry who self-identify as African American, African, or Afro-Caribbean

Diagnosed with non-diabetic chronic kidney disease (CKD)

No history of dialysis or kidney transplant

Commitment to Privacy

Your Information. Your Rights. Our Responsibilities.

Eligible patients and healthcare providers have no expectations or obligations to Natera or Vertex Pharmaceuticals to participate in the sponsored Renasight™ Genetic Testing Program.
All tests must be ordered by a qualified healthcare provider based on clinical necessity for the patient. Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.
Natera never distributes identifiable patient data or information. Natera will never share identifiable patient data or information. Vertex Pharmaceuticals and third parties may receive aggregated, de-identified data, and contact information for healthcare providers that participate in this sponsored Renasight™ genetic testing program.
Click here to learn more about how your medical information is used and protected; and, how you can get access to this information.

Learn more about the sponsored Renasight™ genetic testing program

Select your user type to proceed!

I am a

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company *

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

^† APOL1-mediated kidney disease as well as other genetic kidney disease diagnoses can only be made by a healthcare provider when taking into consideration all patient health information, including genetic testing results.

^†† The Sponsored Renasight™ Genetic Testing Program is funded by Vertex Pharmaceuticals Incorporated. Additional terms and conditions apply. This program is subject to change or discontinuation without notice.

^{Eligible patients and healthcare providers have no expectations or obligations to Natera or Vertex Pharmaceuticals to participate in the sponsored Renasight™ Genetic Testing Program.}

^{All tests must be ordered by a qualified healthcare provider based on clinical necessity for the patient. Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.}

^{Natera never distributes identifiable patient data or information. Natera will never share identifiable patient data or information. Vertex Pharmaceuticals and third parties may receive aggregated, de-identified data, and contact information for healthcare providers that participate in this sponsored Renasight™ genetic testing program.}

References

¹Umeukeje EM, Young BA. Genetics and ESKD Disparities in African Americans. Am J Kidney Dis. 2019 Dec;74(6):811-821. doi: 10.1053/j.ajkd.2019.06.006. Epub 2019 Oct 10. PMID: 31606237; PMCID: PMC7373097.

²https://www.niddk.nih.gov/health-information/kidney-disease/race-ethnicity

³Elliott MD et al. J Am Soc Nephrol. 2023;34(5):909-919

Hiding in Plain Sight – Identify APOL1-Mediated Kidney Disease†

Identify APOL1 variants associated with APOL1-mediated kidney disease (AMKD) with Renasight™ sponsored renal genetic testing for eligible* patients of African ancestry††